美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

減肥藥

1,572.68

-0.1226-0.01%

漲家數：- -

跌家數：- -

平家數：- -

市盈率：- -

高：1,591.44

開：1,573.14

低：1,567.96

收：1,572.81

成交量：2,300.29萬

成交額：17.47億

市值：1.64萬億

流通市值：1.57萬億

資料載入中...

總覽新聞資訊

安進（AMGN）聯合療法III期臨床達主要終點

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

市場風向標：安進股價遭受重創

諾和諾德(NVO)股票9月8日收盤下跌3.09%：背後推手曝光

TradingKey中文

傑富瑞表示，隨着投資者等待更多肥胖症臨床試驗數據，Structure股價下跌

安進股價或創二十餘年來最大單日跌幅

諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌

安進(AMGN)股票9月8日盤中下跌8.33%：真相來了

TradingKey中文

BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華

安進股價下跌7%，創下自2025年6月以來最大單日跌幅。

更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標

安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療

Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善

BMO下調安進及BioNTech評級至「與大市同步」

Structure Therapeutics旗下Aleniglipron在Access Ole試驗中展現72周最高16.2%體重降幅

Structure Therapeutics候選藥物Accg-2671展現約6天半衰期，未出現嚴重不良事件，1/2a期SAD試驗中實現3.3%體重下降

Structure Therapeutics宣佈ACCG-2671在12周MAD 1/2a期試驗完成首批受試者給藥，頂線數據預計2027年上半年公布

Structure Therapeutics公布口服小分子Amylin與GLP-1項目在慢性體重管理中的積極臨床數據

美股盤前｜英特爾、甲骨文升逾4%；諾華重挫12%，IONIS下跌10%；阿斯麥新一代EUV光刻機獲台積電和三星使用承諾

老虎资讯综合

諾和諾德（NVO）跌1.24% 叫停ziltivekimab兩項後期試驗管線再遇挫折

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK4599/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"減肥藥","latestPrice":1572.6842,"timestamp":1789489814534,"preClose":1572.8068,"halted":0,"volume":23002929,"delay":0,"changeRate":-0.000078,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-0.122559,"latestTime":"09-15 12:30:14 EDT","open":1573.1395,"high":1591.4413,"low":1567.9567,"amount":1747356864.969943,"amplitude":0.014932,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.303144,"peRate":27.31853,"turnoverRate":0.002162,"increases":2,"decrements":5,"flats":0,"marketCap":1639141868544,"floatMarketCap":1574643540416},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1591.4413,"amplitude":0.014932,"preClose":1572.8068,"low":1567.9567,"pbRate":"9.303144","latestPrice":1572.6842,"volume":23002929,"delay":0,"open":1573.1395,"prevYearClose":1494.5856,"prevWeekClose":1548.1692,"prevMonthClose":1629.2258,"prevQuarterClose":1614.7615,"fiveDayClose":1572.5367,"twentyDayClose":1639.1223,"sixtyDayClose":1498.3386,"secType":"PLATE","market":"US","turnoverRate":0.002162,"peRate":27.31853,"marketCap":1639141868544,"floatMarketCap":1574643540416,"timestamp":1789489814534,"nameCN":"減肥藥"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU2468319806.SGD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","BK4581","BIB","AZNH","PJP","LU0889565916.HKD","IE0002141913.USD","LU0128525929.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BBH","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","LU2456880835.USD","LU0708994859.HKD","IBBQ","LU2242646821.SGD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","IBB","LU2236285917.USD","IE00B2B36J28.USD","PBE","LU2237443622.USD","LU0029864427.USD","BK4139","BK4568","BK4534","BK4585","LU2237443382.USD","LU1267930573.SGD","LU2462157665.USD","LU2089984988.USD","TBXU","SG9999001440.SGD","AZN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1023059063.AUD","IBBJ","IBBQ","AMGN","LU0889565916.HKD","BK4588","LU0320765992.SGD","IBB","LU0868494617.USD","LU0058720904.USD","PSYK","BK4139","PBE","BK4533","BIB","IE0002141913.USD","IE00B4R5TH58.HKD","LU1983299246.USD","IE0009355771.USD","BK4566","LU0109394709.USD","BK4581","SG9999001440.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2242646821.SGD","LU2468319806.SGD","PJP","LU1571399168.USD","TBXU","BBH","LU2242652126.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","BK4585","IE00B2B36J28.USD","MDTX","IE00BJJMRZ35.SGD","BK4599","LU2112291526.USD","LU0122379950.USD","BK4534","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市場風向標：安進股價遭受重創","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"us","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1023059063.AUD","LU0868494617.USD","PBE","LU1983299246.USD","IE00B4R5TH58.HKD","LU2112291526.USD","BK4534","IBBQ","LU0289739699.SGD","LU0320765992.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","AMGN","IE00BJJMRZ35.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU2242646821.SGD","IBB","LU1057294990.SGD","IE0009355771.USD","BIB","IE0002141913.USD","LU2089984988.USD","PJP","BK4581","SG9999001440.SGD","BK4599","BBH","TBXU","BK4566","BK4533","LU2242652126.USD","BK4585","LU2468319806.SGD","LU0058720904.USD","LU1571399168.USD","LU0109394709.USD","LU0122379950.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666772413","title":"諾和諾德(NVO)股票9月8日收盤下跌3.09%：背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2666772413","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666772413?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:16","pubTimestamp":1788898589,"startTime":"0","endTime":"0","summary":"• 诺和诺德因试验无效终止了两项齐妥珠单抗（ziltivekimab）的 3 期晚期临床试验。\n• 司美格鲁肽（semaglutide）STEP Young 试验的积极结果未能提振市场情绪。\n• 技术指标显示出 MACD 卖出信号，且威廉指标（Williams %R）处于超卖状态。","market":"us","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156841-market-movers-nvo-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","BK4599","LU0154236417.USD","PPH","NVOX","IE00BKVL7J92.USD","NVO","BK4532","LU1093756325.SGD","NVOH","BK4007","THNR","IE00BZ1G4Q59.USD","NVOC","BK4585","BK4588","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372108","title":"傑富瑞表示，隨着投資者等待更多肥胖症臨床試驗數據，Structure股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372108","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372108?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 03:48","pubTimestamp":1788896882,"startTime":"0","endTime":"0","summary":"BUZZ-杰富瑞表示，随着投资者等待更多肥胖症临床试验数据，Structure股价下跌9月8日-** Structure Therapeutics（GPCR.O）股价下跌13.4%，至40.73美元** 杰富瑞（Jefferies）表示，Structure公布试验数据后股价走弱与数据集本身无关，无论是试验结果还是公开电话会议中均未出现任何基本面问题** 当日早些时候，Structure公布了其实验","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S4501KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安進股價或創二十餘年來最大單日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111756325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"us","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BBH","IE00B2B36J28.USD","AMGN","LU1061106388.HKD","LU0889565916.HKD","BK4566","LU0058720904.USD","04332","IE0009355771.USD","BK4588","IBB","LU0109394709.USD","LU0868494617.USD","BIB","LU1571399168.USD","LU1057294990.SGD","LU1023059063.AUD","LU2089984988.USD","PJP","LU2242652126.USD","LU2468319806.SGD","BK4534","TBXU","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0289739699.SGD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU2242646821.SGD","PBE","BK4599","IBBQ","SG9999001440.SGD","BK4581","LU0122379950.USD","BK4533","BK4139","LU0320765992.SGD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371445","title":"諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371445","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371445?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 00:41","pubTimestamp":1788885660,"startTime":"0","endTime":"0","summary":"——Royalty Pharma** RPRX重申“其2030年投资组合收入目标为47亿美元或更高”** 计入本交易日涨幅，该股今年以来累计上涨54.7%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4501DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","LU0289739699.SGD","LU1061106388.HKD","TBXU","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0889565916.HKD","LU1571399168.USD","LU2089984988.USD","LU0122379950.USD","LU2468319806.SGD","LU1057294990.SGD","LU1983299246.USD","IE00BFTCPJ56.SGD","BK4581","BK4007","BIB","LU0868494617.USD","LU1023059063.AUD","SG9999001440.SGD","BK4599","BK4588","IHE","IBBQ","IE00BJJMRZ35.SGD","BBH","LU0058720904.USD","IBB","LU0109394709.USD","IE0002141913.USD","RPRX","LU2242652126.USD","BK4139","PJP","LU0320765992.SGD","BK4533","IE00B4R5TH58.HKD","PBE","IE0009355771.USD","IONS","BK4566","BK4534","AMGN","BK4585","LU2112291526.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376637","title":"安進(AMGN)股票9月8日盤中下跌8.33%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376637","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376637?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:16","pubTimestamp":1788876978,"startTime":"0","endTime":"0","summary":"• 诺华 pelacarsen 试验失败，加大了安进竞品 olpasiran 的临床不确定性。\n• 出于对估值的担忧，BMO Capital 将安进的评级从“跑赢大盘”下调至“与大盘持平”。\n• 技术指标显示，安进的 RSI 为 40.256，威廉指标（Williams %R）为 97.857。","market":"sg","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156239-market-movers-amgn-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","SG9999001440.SGD","LU2112291526.USD","LU1023059063.AUD","BIB","BBH","IBB","IE00B2B36J28.USD","LU0122379950.USD","BK4534","LU1061106388.HKD","LU2242652126.USD","PJP","BK4533","LU2089984988.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","BK4581","TBXU","LU1057294990.SGD","LU2242646821.SGD","BK4588","LU0868494617.USD","IE00B4R5TH58.HKD","BK4585","LU0109394709.USD","LU1571399168.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4566","AMGN","LU0289739699.SGD","IE0009355771.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","BK4599","IBBQ","LU0889565916.HKD","LU1983299246.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375206","title":"BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375206","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:58","pubTimestamp":1788875887,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Sigma Lithium、Shake Shack、诺华工作区中用于查询单只股票行情的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透9月8日-周二开盘时，华尔街主要股指涨跌不一，中东地区新一轮冲突推动油价升至7月下旬以来的最高水平，而市场正在等待本周晚些时候","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S45014M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU1548497426.USD","BK4566","IE00B66KJ199.SGD","LU0345769631.USD","BK4131","BE","LU1861559042.SGD","UPGR","BSX","IE00BBT3K403.USD","IONC","IONS","LU0868494617.USD","LU2264538146.SGD","PBE","LU2357125470.USD","BK4504","LU2357305700.SGD","LU0306806265.USD","LU0058720904.USD","LU0128526141.USD","FRNW","LU0138981039.USD","IE00BJT1NW94.SGD","LU1066053197.SGD","LU1093756168.USD","LU1366192091.USD","LU0320765992.SGD","LU2491050071.SGD","LU0070302665.USD","LU0187121727.USD","ICLN","IE000M9KFDE8.USD","BK4556","BK4179","BEG","LU0433182093.SGD","IE00B3T34201.USD","LU1023059063.AUD","SHAK","LU0456855351.SGD","BK4567","SMOG","LU0122379950.USD","BK4209","LU1989764748.USD","LU2491049909.HKD","XES","IE00BLSP4239.USD","EGGY","CTEC","LU1571399168.USD","LU1066051498.USD","LU2543165471.USD","BEC","BK4120","LU0321505439.SGD","LU0823414478.USD","LU1878469433.USD","BK4533","LU0320765489.SGD","PHVS","LU1291159041.SGD","LU1989764664.SGD","LU0476273544.USD","RGTX","LU2242649171.HKD","LU0306807586.USD","BK4121","LU0345769128.USD","LU0823414551.USD","LU0985489474.SGD","LU0225771236.USD","BK4141","LU1720051108.HKD","LU1057294990.SGD","OZEM","BK4588","IE00B7SZL793.SGD","IE0031619046.USD","LU2265009873.SGD","LU2242646821.SGD","WQTM","TBXU","BK4585","LU1989772840.SGD","04332","LU2294711713.HKD","BK4168","IE00B19Z3B42.SGD","LU0234572021.USD","IONQ","LU0957808578.USD","OIH","PJP","LU1894683348.USD","BK4599","CQTM","ROIV","LU1720051017.SGD","SRPT","LU2468319806.SGD","SG9999001176.SGD","LU1983299246.USD","BK4534","LU0077335932.USD","LU0211331839.USD","USNG","BK4102","ALV","IE0009354923.USD","PPH","LU0353189763.USD","CHRW","LU0823416689.USD","RGTU","LU0114720955.EUR","LU0444971666.USD","LU2362540622.SGD","QTUP","LU0011850046.USD","DYN","LU0029874061.USD","LU1791710582.SGD","LU0878866978.SGD","SGML","VTWG","RGTC","IBAT","LU0225283273.USD","LU2087625088.SGD","BK4602","IE00B19Z4B17.USD","BK4578","IOYY","WATS","SEI","LU1153585028.USD","LU2362541513.USD","LU2506952170.USD","BK4581","LU1061106388.HKD","LU2249611893.SGD","LU0170899867.USD","LU0048584097.USD","LU0353189680.USD","BIB","LU0266013472.USD","VCLN","UNFI","LU0882574055.USD","SGXZ57979304.SGD","LU0889565916.HKD","SG9999001440.SGD","LU0289739699.SGD","NTLA","IONL","HYDR","IE00BJJMRZ35.SGD","LU2098885051.SGD","BK4592","IBBQ","LU2491050154.USD","BK4541","SG9999002232.USD","BK4124","IE0009355771.USD","LU2506951958.HKD","BK4597","LU1989772923.USD","LU0238689110.USD","BK4082","LU0985481810.HKD","LU1883839398.USD","LU2506951792.HKD","LU2596442595.SGD","LU0068578508.USD","LU0225284248.USD","MEDX","IE00B4R5TH58.HKD","LU1064131342.USD","LU1791710400.SGD","BEZ","IE00BFTCPJ56.SGD","BK4591","BK4532","LU1804176565.USD","LU2362541273.HKD","RGTZ","LU0950375773.USD","LU1642822529.SGD","LU0432979614.USD","LU2324357040.USD","IE0002270589.USD","SG9999002224.SGD","LU2242652126.USD","BEX","IONX","LU0109394709.USD","LU0528227936.USD","LU2244417387.USD","BBH","IE00BLSP4452.SGD","SG9999003800.SGD","BK4139","LU1894683264.USD","GNOM","BK4568","ILMN","RGTI","BK4170","IE0002141913.USD","RGYY","LU1718418525.SGD","LU1989771016.USD","IBB","SG9999001176.USD","CNRG","LU2089984988.USD","LU0208291251.USD","LU2506951875.HKD","LU1489326972.SGD","ABM","BK4548","SG9999011175.SGD","LU0251132253.USD","LU1815336760.USD","BK4182","GNMX","LU2112291526.USD","LU0823417653.USD","LU1988902786.USD","BK4505","SIMS","LU0823417737.USD","BK4007","BK4535","NVS","LU0321505868.SGD","IE00B2B36J28.USD","IONZ","LU0444973449.USD","LU1093756325.SGD","LU1861558580.USD","SG9999013999.USD","PTH","SRPU","BK4550","IE00B19Z3581.USD","LU0267386448.USD","LU1303367103.USD","ZAP","PFE","IE0034235188.USD","BHVN","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375527","title":"安進股價下跌7%，創下自2025年6月以來最大單日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:30","pubTimestamp":1788874246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BIB","LU0058720904.USD","IE0009355771.USD","BK4533","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU2242652126.USD","SG9999001440.SGD","BK4599","LU0109394709.USD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2089984988.USD","LU1061106388.HKD","AMGN","BK4139","LU2242646821.SGD","BK4585","LU2112291526.USD","TBXU","IE00B2B36J28.USD","LU0122379950.USD","BK4566","IE00B4R5TH58.HKD","LU1571399168.USD","LU2468319806.SGD","PBE","LU0320765992.SGD","IBBQ","BK4588","LU0289739699.SGD","LU0868494617.USD","PJP","LU1023059063.AUD","BK4581","LU1983299246.USD","IBB","BK4534","IE00BJT1NW94.SGD","IE0002141913.USD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732793","title":"更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732793","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873260,"startTime":"0","endTime":"0","summary":"阿斯利康抗癌药物组合在晚期临床试验中达到主要生存目标路透9月8日-阿斯利康（AstraZeneca）AZN.L周二表示，其抗癌药物Imfinzi与安进（Amgen）的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中，显著提高了广泛期小细胞肺癌一线治疗患者的总生存期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S450114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880407132.USD","LU1084165304.USD","LU1487256676.USD","LU0827474353.SGD","LU0997586515.USD","LU0969580561.USD","LU0882574055.USD","IBBQ","LU0784383803.USD","IBB","LU0058720904.USD","LU0957799991.USD","LU1863844749.USD","LU2433249047.HKD","LU1023059063.AUD","BBH","BIB","PBE","PJP","LU0109394709.USD","LU0661504455.SGD","AMGN","LU1003076772.USD","LU1923622614.USD","LU1046234339.USD","LU0077335932.USD","LU1061106388.HKD","LU0289739699.SGD","LU2355687059.USD","03165","LU1829250122.USD","LU2242652126.USD","LU0203347892.USD","BK4139","LU2279689827.SGD","BK4599","LU0122379950.USD","LU0545039389.USD","LU0868494617.USD","TBXU","LU2091194634.USD","LU0920783379.SGD","IE0034235188.USD","LU0526926950.USD","LU1481599808.USD","LU0889566641.SGD","LU1170363599.USD","LU2237443465.HKD","AZN.UK","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115495471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU1057294990.SGD","BK4585","BK4581","LU0868494617.USD","BK4599","LU1983299246.USD","LU0058720904.USD","IBB","IE00B4R5TH58.HKD","LU1571399168.USD","SG9999001440.SGD","LU2089984988.USD","PJP","IBBQ","LU0289739699.SGD","BK4588","BBH","BK4534","LU1023059063.AUD","IE0009355771.USD","LU0889565916.HKD","LU2242652126.USD","IE00BJJMRZ35.SGD","BIB","PBE","AMGN","IE00BJT1NW94.SGD","LU0320765992.SGD","LU1061106388.HKD","IE00B2B36J28.USD","LU2242646821.SGD","LU0109394709.USD","IE0002141913.USD","TBXU","LU2112291526.USD","BK4533","IE00BFTCPJ56.SGD","BK4139","BK4566","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109517247?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","BK4534","IE0002141913.USD","BK4566","LU0122379950.USD","LU2468319806.SGD","BBH","LU2112291526.USD","BK4533","IE00B4R5TH58.HKD","AMGN","LU1571399168.USD","BK4581","BK4599","IE00BJT1NW94.SGD","BK4585","LU0058720904.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU2242646821.SGD","LU0868494617.USD","IBB","PBE","LU0889565916.HKD","BIB","LU1057294990.SGD","BK4588","LU1061106388.HKD","BK4139","LU1983299246.USD","IBBQ","PJP","LU2242652126.USD","LU0109394709.USD","LU1023059063.AUD","LU2089984988.USD","IE00BFTCPJ56.SGD","SG9999001440.SGD","LU0289739699.SGD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下調安進及BioNTech評級至「與大市同步」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665387373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BFTCPJ56.SGD","LU0058720904.USD","LU1023059063.AUD","LU2089984988.USD","BK4599","BBH","LU2112291526.USD","LU2242646821.SGD","LU1061106388.HKD","IE0002141913.USD","BK4566","LU2468319806.SGD","LU0889565916.HKD","BK4585","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","TBXU","SG9999001440.SGD","LU1983299246.USD","BK4581","IBBQ","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","IBB","LU0289739699.SGD","LU0122379950.USD","BK4534","LU2242652126.USD","LU0109394709.USD","PJP","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","BIB","LU1057294990.SGD","LU1571399168.USD","LU0868494617.USD","PBE","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165843596","title":"Structure Therapeutics旗下Aleniglipron在Access Ole試驗中展現72周最高16.2%體重降幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1165843596","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165843596?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788868999,"startTime":"0","endTime":"0","summary":"Structure Therapeutics宣布，其候选药物Aleniglipron在Access Ole临床试验中取得了令人瞩目的成果——患者在72周的治疗周期内，体重减轻幅度最高达到16.2%。这一数据标志着该药物在长期减肥疗效方面迈出了坚实一步。此次公布的临床试验结果无疑为Structure Therapeutics注入了强劲动力。在长达72周的观察窗口内，Aleniglipron不仅展现出持续且显著的减重效果，更凸显了其在肥胖症治疗领域的巨大潜力。值得注意的是，这一长期数据进一步巩固了Aleniglipron的安全性及耐受性轮廓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4007","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129991235","title":"Structure Therapeutics候選藥物Accg-2671展現約6天半衰期，未出現嚴重不良事件，1/2a期SAD試驗中實現3.3%體重下降","url":"https://stock-news.laohu8.com/highlight/detail?id=1129991235","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129991235?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788868989,"startTime":"0","endTime":"0","summary":"Structure Therapeutics披露了其研发管线中备受关注的候选药物Accg-2671的最新临床数据。\n该公司表示，该药物在1/2a期单次递增剂量（SAD）临床试验中，展现出大约6天的半衰期特征。\n在安全性方面，研究过程中未观察到任何严重不良事件，表现令人鼓舞。\n此外，试验数据显示，受试者体重出现3.3%的下降幅度。这一系列积极结果或将为该药物后续的临床开发奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164454119","title":"Structure Therapeutics宣佈ACCG-2671在12周MAD 1/2a期試驗完成首批受試者給藥，頂線數據預計2027年上半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1164454119","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164454119?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:02","pubTimestamp":1788868934,"startTime":"0","endTime":"0","summary":"Structure Therapeutics日前披露，其候选药物ACCG-2671在为期12周的多剂量递增1/2a期临床试验中，已完成首批受试者给药。据悉，这项研究旨在评估ACCG-2671的安全性、耐受性及药代动力学特征，为后续更为深入的疗效验证奠定基础。公司方面表示，该试验的顶线数据预计将于2027年上半年对外公布。市场分析人士认为，ACCG-2671若能按期交出令人满意的数据，或将进一步巩固Structure Therapeutics在代谢及心血管疾病治疗领域的前沿地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173437492","title":"Structure Therapeutics公布口服小分子Amylin與GLP-1項目在慢性體重管理中的積極臨床數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1173437492","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173437492?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868877,"startTime":"0","endTime":"0","summary":"Structure Therapeutics对外披露，其在口服小分子Amylin及GLP-1项目中，收获了针对慢性体重管理的积极临床数据。此番成果，无疑为该公司在代谢性疾病治疗领域的布局注入了强劲动力。这些发现，不仅彰显了其研发管线的潜力，也或将为未来肥胖症治疗开辟新的路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103332998","title":"美股盤前｜英特爾、甲骨文升逾4%；諾華重挫12%，IONIS下跌10%；阿斯麥新一代EUV光刻機獲台積電和三星使用承諾","url":"https://stock-news.laohu8.com/highlight/detail?id=1103332998","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103332998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:01","pubTimestamp":1788868860,"startTime":"0","endTime":"0","summary":"9月8日美元指数上升0.0364%，报98.96。03 要闻1. 三大芯片厂全面采购ASML最先进High NA EUV光刻机以扩产高端制程。ASML确认三星、台积电与英特尔已承诺在2028–2030年起量产使用High NA设备，并与ASML签订光罩尺寸升级合作协议，助力降低AI芯片制造成本。","market":"hk","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823039010.USD","IE000BZT7R73.USD","PXI","IE00BKVL7J92.USD","BK4591","LU1935043023.USD","LU2111349929.HKD","LU1894683348.USD","LU2250418816.HKD","LU1718418525.SGD","CHPX","LU2087625088.SGD","IE00BLSP4452.SGD","BK4612","LU1316542783.SGD","LU1074936037.SGD","IGE","NVS","LU2108987350.USD","UDOW","LU1066053197.SGD","LU2471134952.CNY","LU0661504455.SGD","CHPS","IE00BMPRXR70.SGD","AVSE","LU1712237335.SGD","LU1815336760.USD","LU1989772923.USD","LU2764263039.SGD","LU0081259029.USD","LU0072461881.USD","LU1988902786.USD","BK4533","LU0124676726.USD","BK4588","LU2028103732.USD","AVXC","LU2347655156.SGD","CGIC","LU0300736062.USD","SPY","LU0238689110.USD","IE0002141913.USD","LU0154236417.USD","LU0321505439.SGD","LU1048588211.SGD","LU1974910355.USD",".DJI","IE00B4R5TH58.HKD","LU1201861249.SGD","IE00BFXG1179.USD","LU0130103400.USD","LU0158827781.USD","LU2242649171.HKD","LU0162691827.USD","LU0234572021.USD","RSPG","LU1267930490.SGD","SG9999014559.SGD","IE00B19Z3581.USD","LU1153585028.USD","LU0359201885.HKD","LU1935042215.USD","AIQ","IE00BKPKM429.USD","CGDG","BK4585","LU0965509101.SGD","BK4548","LU0417517546.SGD","LU1282649067.USD","LU2360108059.USD","LU0345769631.USD","LU2247934214.USD","LU2720916845.USD","LU0787776722.HKD","DXD","IE000MB6IJN5.SGD","LU1267930227.SGD","BK4157","LU0572939691.SGD","LU2211814178.USD","LU2087621335.USD","BK4170","LU1046421795.USD","LU2133065610.SGD","IBB","FTXN","LU0274383776.USD","LU0528227936.USD","LU0143551892.USD","BK4138","LU0949170772.SGD","LU2506952170.USD","LU0314106906.USD","LU2324357040.USD","AIS","LU2272731865.HKD","LU2360032135.SGD","LU0889565833.HKD","BK4566","IE000SO60NU8.SGD","LU0965508806.USD","LU1778281490.HKD","IE00B19Z4B17.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0345774631.USD","IE000F7OJYX1.SGD","IYE","SGXZ99366536.SGD","LU0084288322.USD","SG9999014542.SGD","IE0009355771.USD","LU1267930813.SGD","BIB","LU0203347892.USD","LU0256863811.USD","LU2999663052.SGD","LU0109394709.USD","LU2362541273.HKD","LU0143863198.USD","SG9999000418.SGD","SGXZ57979304.SGD","LU2750360641.GBP","LU0011850046.USD","SG9999011175.SGD","SG9999015358.SGD","FCG","IE00B7SZLL34.SGD","LU0094547139.USD","LU0823421333.USD","LU1992135399.USD","LU0158827948.USD","QTUP","IE0000B7K699.USD","LU1282649810.SGD","LU0738911758.USD","BGIA","LU0316494557.USD","SG9999002224.SGD","LU0267386448.USD","LU0882574055.USD","LU1868838027.USD","IE00B775SV38.USD","LU0266512473.USD","LU1804176565.USD","BK4599","LU0320765489.SGD","ORCZ","BBH","LU2357627491.SGD","BK4515","LU2272731782.SGD","IE00BQXX3F31.USD","LU1435385759.SGD","LU1989764748.USD","BK4543","LU0572940350.SGD","LU0868494708.USD","IE00BFXG0V08.USD","ORCS","EMM","TEK","BK7104","TEXU","LU1674673428.USD","DOG","LU2054465674.USD","IE00BN8TJ469.HKD","LU0097036916.USD","LU1720051108.HKD","LU0170899867.USD","DRLL","INYY","LU1037948897.HKD","LU2272731600.USD","ORCX","LU2211815571.USD","LU1868837565.USD","LU0109392836.USD","LU0345774391.USD","LU0868486357.SGD","LU0300736492.USD","LU1732799900.SGD","LU0878004406.USD","LU2112291526.USD","XNTK","03145","LU0251131958.USD","CNEQ","LU1093756168.USD","LU2360107168.USD","LU0957791311.USD","LU0689626769.HKD","LU0642271901.SGD","CTEX","LU0320765646.SGD","LU0211327993.USD","SG9999002521.SGD","LU2326559502.SGD","BK4516","GNMX","LU0912757837.SGD","LU1366192091.USD","LU2505996681.GBP","SG9999014575.USD","LU0310799852.SGD","HK0000304805.HKD","LU0823038988.USD","IE00B2B36J28.USD","LU2264538146.SGD","LU1023059063.AUD","LU1003077747.HKD","LU0965509283.SGD","LU0211331839.USD","QQQA","LU1791710582.SGD","TRUN","LU1066051498.USD","THNR","BK4512","WQTM","BLOX","LU0985489474.SGD","LU0068578508.USD","VDE","LU1642822529.SGD","LU0612318385.USD","LU0719512351.SGD","LU0029874061.USD","LINT","LU1093756325.SGD","LU0266512127.USD","LU2491050071.SGD","LU0795875169.SGD","LU1934455194.USD","DIG","LU0466842654.USD","LU0859254822.USD","LU2468319806.SGD","LU2473716301.USD","ORCL","LU0496365809.HKD","TNGY","BK4007","LU0234570918.USD","LU2023251221.USD","LU1064131342.USD","LU2290526834.HKD","WEEI","LU2041044095.USD","LU0889566641.SGD","LU0553294199.USD","IE0004086264.USD","LU2360106780.USD","IE0004445239.USD","BK4527","IE00B5TLWC47.USD","LU0433182093.SGD","FENI","LU2543165471.USD","TINS","LU0444971666.USD","LU1366333091.USD","LU1989771016.USD","WUGI","LU1815333072.USD","LU0541501648.USD","LU0868494617.USD","LU0048584097.USD","LU1803068979.SGD","BK4526","CGNG","LU0889565916.HKD","LU0149725797.USD","LU1989764664.SGD","LU2487616109.SGD","LU0187121727.USD","EPAI","IE0034235303.USD","GNOM","LU0122376428.USD","LU1934455277.USD","LU2089283258.USD","IE00BGHQF524.EUR","LU0130517989.USD","LU2458330169.SGD","GSID","LU0878005551.USD","SG9999001424.SGD","DBEU","LU0823417737.USD","LU1582986359.USD","ORCU","LU0353189680.USD","ADVE","LU0788109394.HKD","LU1823568750.SGD","LU1791710400.SGD","SG9999013999.USD","SG9999004220.SGD","BK4570","LU0476273544.USD","BK4532","LU0368265418.SGD","IE000WAW04H5.SGD","IE00BWXC8680.SGD","IE00BLSP4239.USD","LU2265009873.SGD","LU0431992006.USD","BK4592","LU0980610538.SGD","LU2237957811.SGD","LU0683600562.USD","LU2471134879.HKD","LU0114720955.EUR","LU2746668974.SGD","BK4535","CQTM","LU0348723411.USD","LU1623119135.USD","LUMA","LU0130102774.USD","LU1211504680.USD","LU2089985449.USD","IE00BQXX3C00.GBP","LU1992135472.HKD","LU1935042488.USD","LU0289960550.SGD","LU0823434740.USD","DDM","IE00BQXX3D17.EUR","LU0056508442.USD","LU0058720904.USD","LU2746668461.USD","LU0098860793.USD","LU0061474960.USD","CGGO","LU2089984988.USD","LU2242652126.USD","IE00B1XK9C88.USD","LU0359201612.USD","LU2089284900.SGD","BK4538","SG9999003800.SGD","TDIV","LU0211326755.USD","LU1037948541.HKD","LU2092937221.SGD","LU0345780950.USD","LU0654597011.USD","TBXU","LU1934455863.HKD","LU0882747503.HKD","LU0792757196.USD","LU0823416689.USD","SPWO","INTW","LU0976567544.SGD","IE00BMPRXN33.USD","BK4504","LU1323610961.USD","FOTO","DRIV","LU0251132253.USD","IE0004091025.USD","LU2271345857.HKD","LU1506573853.SGD","LU1057294990.SGD","BK4602","IE00BZ1G4Q59.USD","IE00BMPRXQ63.HKD","LU1430594728.SGD","LU0345769128.USD","LU2462591277.SGD","FFGX","OGIG","LU0211326839.USD","LU0942090050.USD","LU0345781412.USD","LU0950375773.USD","BK4148","KNOW","SGXZ51526630.SGD","LU1150488135.SGD","SG9999014567.USD","LU1582987324.SGD","DBEF","ESIM","LU2125154778.USD","LU0353189763.USD","LU2462611646.USD","OZEM","LU1430597077.USD","LU2362540622.SGD","LU0070302665.USD","IE00BBT3K403.USD","LU2298321311.HKD","LU2244417387.USD","LU0742534661.SGD","HBMX","IE00B66KJ199.SGD","LU1035773651.USD","LU2506951958.HKD","LU1883866441.USD","EFA","LU0143863784.USD","LU2505996509.AUD","LU2506951792.HKD","SPTE","IE00B19Z3B42.SGD","IE00BD6J9T35.USD","SG9999001176.SGD","BK4097","GXPE","LU1917777945.USD","LU1861220033.SGD","SG9999001176.USD","LU0878866978.SGD","LU0082616367.USD","SMH","BK4139","LU0052756011.USD","LU0128526141.USD","LU0359202008.SGD","IE0009356076.USD","LU1734074674.USD","BK4578","LU0157215616.USD","LU2294711713.HKD","CRAK","LU2458330243.SGD","LU2506952097.USD","LU2129689605.HKD","BK4554","INTC","LU0266013472.USD","LU1861215975.USD","LU1989772840.SGD","UMMA","03165","ERX","PBE","LEGR","SPRX","BK4608","LU2860962120.EUR","LU0456854461.SGD","BK4575","IE00BYQQ9H92.USD","LU0957808578.USD","PXE","LU0128525689.USD","IXC","IEO","LU0648001328.SGD","IGV","LU0072462343.USD","LU2491049909.HKD","BK4213","LU1894683264.USD","LU0965509010.AUD","LU1983299246.USD","IEFA","LU1508157978.USD","LU1852331112.SGD","LU1023057109.AUD","ILOW","IFLR","LU1201861165.SGD","SDOW","BK4023","LU0077335932.USD","LU2237957902.USD","LU2237443549.SGD","LU2602419157.SGD","IE00BZ199S13.USD","LU0310800965.SGD","LU2357305700.SGD","LU0823414478.USD","IE00B2Q91V27.USD","IE0002270589.USD","LU2102340556.USD","LU2471134523.USD","ASMH","BK4581","LU2592432038.USD","PJP","LU0545039389.USD","LU2129689514.USD","IE000M9KFDE8.USD","IE00B3CCJ963.GBP","LU1429558221.USD","LU2125154935.USD","LU2663582299.SGD","LU0861579265.USD","PPH","CORO","IE00B7SZL793.SGD","PQNT","ORAC","LU0541502299.USD","LU1691799644.USD","FDTX","LU0795875086.SGD","BK4147","LU1732800096.USD","LU1839511570.USD","CNAV","LU0138981039.USD","LU0345770993.USD","LU1674673691.USD","LU2237443622.USD","BK4503","LU2362541513.USD","SG9999002232.USD","LU1489326972.SGD","IE00B3S45H60.SGD","LU2242646821.SGD","MEDX","OILT","LU0630314457.HKD","SG9999001440.SGD","LU0070217475.USD","IE00BSNM7G36.USD","BK7095","LU2148611432.USD","LU0211328371.USD","LU0264606111.USD","LU2430703095.HKD","LU0198837287.USD","LU2896262040.SGD","LU1582986433.USD","BK4201","LU0203345920.USD","LU2129689431.USD","EMC","DIA","BK4605","LU2764262908.HKD","LU2931357623.SGD","BK4505","LU2357125470.USD","INT","LU0823414551.USD","XLE","LU0612318971.USD","LU2249611893.SGD","LU0278409577.USD","IE00B5949003.HKD","LU0323591593.USD","LU1935043536.SGD","BK4141","LU1061106388.HKD","BK4579","IE00BKDWB100.SGD","HYDR","LU0208291251.USD","SGXZ81514606.USD","LU0251142724.SGD","LU2750360997.AUD","LU1868837722.USD","LU0488056044.USD","IE00BHPRN162.USD","LU0823421416.USD","LU1150488218.USD","LU0384037296.USD","LU2430703178.SGD","BK4082","LU2471134796.USD","IE00B3M56506.USD","LU1571399168.USD","BK4559","BK4550","IE00BFTCPJ56.SGD","LU0345770308.USD","LU0048573561.USD","LU0210528500.USD","LU2491050154.USD","SOXX","LU0122379950.USD","LU0154245673.USD","BK4528","HK0000304797.USD","LU0648000940.SGD","LU0823417653.USD","TTEQ","CHAT","AVEM","LU1235294995.USD","IBBQ","LU0477156953.USD","LU0321505868.SGD","LU2322448791.USD","LU0320765992.SGD","LU0154245756.USD","LU1585245621.USD","FTXL","LU1935042991.SGD","LU1929549753.HKD","LU2430703251.USD","BK4121","LU2506951875.HKD","LU0225283273.USD","LU2764263203.CNY","LU2236285917.USD","LU0432979614.USD","BAI","LU0444973449.USD","LU0256331488.USD","LU1548497426.USD","LU1582987597.SGD","SG9999015341.SGD","LU1720051017.SGD","LU2063271972.USD","LU2237443978.SGD","LU2237443382.USD","BK4534","FENY","LU2322448957.HKD","LU0175139822.USD","IE0031619046.USD","LU0823434583.USD","LU2023250504.SGD","ASIA","LU2498475776.HKD","LU2106854487.HKD","LU2954938101.SGD","LU1069347547.HKD","LU0210536198.USD","EGGY","IE00B1BXHZ80.USD","MEMX","CWI","LU0053666078.USD","BK4529","LU1162221912.USD","LU1291159041.SGD","BK5113","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665321472","title":"諾和諾德（NVO）跌1.24% 叫停ziltivekimab兩項後期試驗 管線再遇挫折","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321472","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321472?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:04","pubTimestamp":1788861897,"startTime":"0","endTime":"0","summary":"消息面上，诺和诺德宣布，提前终止在研心脏候选药物ziltivekimab的两项后期临床试验，公司研发管线再添新的挫折。不过，针对心梗后康复患者的另一项ziltivekimab临床试验仍将继续推进，预计2027年上半年读出试验结果。ziltivekimab被诺和诺德寄予厚望，公司希望借助该药物打开心血管疾病市场，降低对肥胖、糖尿病药物的业务依赖，本次试验终止，对其心血管管线是一次重要打击。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/YzZhYTk2ZjUwYWIwODUzYmVlYzUyNzEyODcxMjIyNA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YzZhYTk2ZjUwYWIwODUzYmVlYzUyNzEyODcxMjIyNA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305804","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","NVOC","NVO","BK4585","IE00BKVL7J92.USD","LU1093756168.USD","PPH","LU1093756325.SGD","BK4599","NVOH","BK4588","OZEM","LU0154236417.USD","BK4007","THNR","NVOX","BK4532"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":74,"code":"91000000","status":"200"}]}}